Keyword: Alnylam Pharmaceuticals
BTI will spend the cash on phase 2 trials of a once-failed cancer asset and an old drug repurposed for use in Alzheimer’s and schizophrenia.
Warp Drive has been working to live up to its name, speeding through development and deals.
Describing a country as a “shithole” isn’t going to endear you to anyone, but President Trump’s latest alleged outburst has struck a nerve with one particular biotech leader.
Barry Greene discusses the retooled Sanofi deal, Alnylam's transition to a commercial-stage company and what's on the horizon in 2018.
The project will see Regeneron sequence the exomes of 500,000 Britons with the financial backing of AbbVie, Alnylam, AstraZeneca, Biogen and Pfizer.
The revised deal returns full global control of the ATTR amyloidosis drug to Alnylam and sees Sanofi obtain worldwide rights to fitusiran.
Alnylam and Sanofi Genzyme submitted the RNAi drug patisiran for EMA approval, just a week after it completed its FDA filing.
Alnylam, which put its hemophilia program on hold in September, has gotten the all-clear from the FDA to resume trials.
The gene silencing pioneer expects to complete the submission by the end of the year, setting it up to win approval in the U.S. in 2018.
Data presented by the RNAi pioneer Alnylam suggest its patisiran has the edge over Ionis’ inotersen in terms of safety and efficacy.